{"entity":{"id":"nct07746388","kind":"trial","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","aka":[],"tldr":"A phase 2 trial of cemiplimab in lung cancer, run by University of Maryland, Baltimore, not yet recruiting.","summary":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial is a phase 2, interventional study registered as NCT07746388 by University of Maryland, Baltimore, with a registry enrolment figure of 30 participants, started 2026-09-01 and due to reach its primary completion in 2030-09-01. Interventions recorded: Cemiplimab. Conditions listed: Nsclc; NSCLC Stage II; NSCLC, Stage III; NSCLC Stage IIIB; Resectable Lung Non-Small Cell Carcinoma. Primary outcome: Major pathologic response (MPR). Lung eligibility wording from the registry: \"Participants with histologically confirmed stage II-IIIB(N2) NSCLC (per the 9th International Association for the Study of Lung Cancer) with disease that is considered resectable prior to initiation of systemic therapy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07746388","url":"https://clinicaltrials.gov/study/NCT07746388"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["pdl1-high-nsclc","resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07746388","phase":"2","setting":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","sponsor":"University of Maryland, Baltimore","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07746388/","neighbours":{"cancer":[{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}